abstract |
The inventors studied an antitumor effect of an anti-IL-6 receptor antibody on prostate cancer. As a result, it was found that the anti-IL-6 receptor antibody exhibits an antitumor effect on prostate cancer both in vivo and in vitro. Further, it was found that hPM1 exhibits an antitumor effect through IL-6 receptor. |